{"filing":{"accession_number":"0001171843-26-004428","cik":"0001738021","ticker":"CMPX","company_name":"Compass Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"f8k_070126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/f8k_070126.htm"},"events":[{"id":15600,"run_id":13904,"accession_number":"0001171843-26-004428","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Compass Therapeutics disclosed updated clinical trial data from the COMPANION-002 Phase 2/3 study of its lead candidate tovecimig in biliary tract cancer, showing significant improvements in overall response rate (18.0% vs. 5.3%, p=0.0228) and progression-free survival (4.7 vs. 2.6 months, HR=0.44, p\u003c0.0001). The company announced plans to meet with the FDA and submit a BLA based on these data with potential approval in H2 2027. This represents a material operational/clinical milestone for a development-stage biopharmaceutical company, as the positive Phase 2/3 data and regulatory pathway advancement directly affect the company's near-term value inflection and commercial prospects.","company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13441,"accession_number":"0001171843-26-004428","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Compass Therapeutics disclosed updated clinical trial data from the COMPANION-002 Phase 2/3 study of its lead candidate tovecimig in biliary tract cancer, showing significant improvements in overall response rate (18.0% vs. 5.3%, p=0.0228) and progression-free survival (4.7 vs. 2.6 months, HR=0.44, p\u003c0.0001). The company announced plans to meet with the FDA and submit a BLA based on these data with potential approval in H2 2027. This represents a material operational/clinical milestone for a development-stage biopharmaceutical company, as the positive Phase 2/3 data and regulatory pathway advancement directly affect the company's near-term value inflection and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:15:38.162637+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13441,"accession_number":"0001171843-26-004428","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Compass Therapeutics disclosed updated clinical trial data from the COMPANION-002 Phase 2/3 study of its lead candidate tovecimig in biliary tract cancer, showing significant improvements in overall response rate (18.0% vs. 5.3%, p=0.0228) and progression-free survival (4.7 vs. 2.6 months, HR=0.44, p\u003c0.0001). The company announced plans to meet with the FDA and submit a BLA based on these data with potential approval in H2 2027. This represents a material operational/clinical milestone for a development-stage biopharmaceutical company, as the positive Phase 2/3 data and regulatory pathway advancement directly affect the company's near-term value inflection and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:15:38.162637+00:00","company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","filing_date":"2026-07-01"}]}